Sarah A. O'Dowd - 02 Jan 2025 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Director
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Sarah A. O'Dowd
Issuer symbol
PTGX
Transactions as of
02 Jan 2025
Transactions value $
$0
Form type
4
Filing time
06 Jan 2025, 18:10:39 UTC
Previous filing
17 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Award $0 +5,130 $0.000000 5,130 02 Jan 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Award $0 +6,584 $0.000000 6,584 02 Jan 2025 Common Stock 6,584 $38.98 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date.
F2 The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.